Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Net Income (2022 - 2025)

Coya Therapeutics' Net Income history spans 4 years, with the latest figure at -$2.4 million for Q3 2025.

  • For Q3 2025, Net Income rose 45.33% year-over-year to -$2.4 million; the TTM value through Sep 2025 reached -$19.9 million, down 88.25%, while the annual FY2024 figure was -$14.9 million, 86.31% down from the prior year.
  • Net Income for Q3 2025 was -$2.4 million at Coya Therapeutics, up from -$6.1 million in the prior quarter.
  • Across five years, Net Income topped out at $1.8 million in Q4 2023 and bottomed at -$7.3 million in Q1 2025.
  • The 4-year median for Net Income is -$3.3 million (2023), against an average of -$3.3 million.
  • The largest annual shift saw Net Income soared 190.6% in 2023 before it crashed 324.79% in 2024.
  • A 4-year view of Net Income shows it stood at -$2.0 million in 2022, then skyrocketed by 190.6% to $1.8 million in 2023, then plummeted by 324.79% to -$4.1 million in 2024, then skyrocketed by 40.37% to -$2.4 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Net Income are -$2.4 million (Q3 2025), -$6.1 million (Q2 2025), and -$7.3 million (Q1 2025).